121 related articles for article (PubMed ID: 12785124)
1. Safety pharmacology of CKD-602, a novel anticancer agent.
Kim EJ; Lee RK; Suh JE; Han SS; Kim JK
Arzneimittelforschung; 2003; 53(4):272-9. PubMed ID: 12785124
[TBL] [Abstract][Full Text] [Related]
2. General pharmacology of IY-81149, a new proton pump inhibitor.
Kim EJ; Lee RK; Lee SM; Kim DY
Arzneimittelforschung; 2001 Jan; 51(1):51-9. PubMed ID: 11215326
[TBL] [Abstract][Full Text] [Related]
3. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
Furuta S; Shimada O; Doi N; Ukai K; Nakagawa T; Watanabe J; Imaizumi M
Arzneimittelforschung; 2004; 54(12):868-80. PubMed ID: 15646371
[TBL] [Abstract][Full Text] [Related]
4. General pharmacological properties of YJA 20379-1, a novel proton pump inhibitor with antiulcer activities.
Lee EB; Cho SI; Cheon SA; Chang MS; Kim KB; Sohn SK; Chung YK
Arzneimittelforschung; 1999 Dec; 49(12):1018-24. PubMed ID: 10635448
[TBL] [Abstract][Full Text] [Related]
5. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
[TBL] [Abstract][Full Text] [Related]
7. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
9. General pharmacological properties of muroctasin.
Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
11. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
12. General pharmacology of the new antiviral agent SK 1899.
Ryu KH; Rhee HI; Jung I; Kim TS; Lee SJ; Im GJ; Lee N; Ryu DH; Kim YW; Kim JJ; Chang K; Lee BH; Shin HS; Kim EJ; Kim KH; Kim DK
Arzneimittelforschung; 2000 Apr; 50(4):395-403. PubMed ID: 10800640
[TBL] [Abstract][Full Text] [Related]
13. [General pharmacologic studies on the analgesic flupirtine].
Jakovlev V; Achterrath-Tuckermann U; von Schlichtegroll A; Stroman F; Thiemer K
Arzneimittelforschung; 1985; 35(1):44-55. PubMed ID: 4039152
[TBL] [Abstract][Full Text] [Related]
14. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.
Algate DR; Augustin J; Atterson PR; Beard DJ; Jobling CM; Laufer S; Munt PL; Tries S
Arzneimittelforschung; 1995 Feb; 45(2):159-65. PubMed ID: 7710439
[TBL] [Abstract][Full Text] [Related]
15. General pharmacology of the new quinolone antibacterial agent levofloxacin.
Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
[TBL] [Abstract][Full Text] [Related]
16. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
17. General pharmacological properties of YJA20379-8, a new H+/K(+)-ATPase inhibitor with anti-ulcer activities.
Lee EB; Cho SI; Chang HO; Chang MS; Kim KB; Lee SB; Choi WS
Arzneimittelforschung; 2001; 51(8):659-66. PubMed ID: 11556127
[TBL] [Abstract][Full Text] [Related]
18. Safety pharmacology of sibutramine mesylate, an anti-obesity drug.
Kim EJ; Park EK; Suh KH
Hum Exp Toxicol; 2005 Mar; 24(3):109-19. PubMed ID: 15901050
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
20. Influence of new monoterpene homologues of GABA on the central nervous system activity in mice.
Librowski T; Czarnecki R; Mendyk A; Jastrzebska M
Pol J Pharmacol; 2000; 52(4):317-21. PubMed ID: 11345489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
